Thinly traded nano cap Annovis Bio (NYSEMKT:ANVS) announces the completion of the rat cohort in a toxicology study of lead drug ANVS401 with no negative side effects.
Results from the six-month study, funded by a
$1.7M NIH grant, corroborated the data generated in one-month studies in
mice, rats, dogs and humans. A nine-month study in dogs is ongoing with
results expected next quarter.
ANVS401 is currently being tested in a Phase 2a clinical trial in Alzheimer’s disease patients.
https://seekingalpha.com/news/3583341-annovis-bio-rallies-on-advancement-of-lead-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.